Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Am J Hum Genet ; 107(3): 527-538, 2020 09 03.
Artigo em Inglês | MEDLINE | ID: mdl-32758447

RESUMO

Generalized pustular psoriasis (GPP) is a severe multi-systemic inflammatory disease characterized by neutrophilic pustulosis and triggered by pro-inflammatory IL-36 cytokines in skin. While 19%-41% of affected individuals harbor bi-allelic mutations in IL36RN, the genetic cause is not known in most cases. To identify and characterize new pathways involved in the pathogenesis of GPP, we performed whole-exome sequencing in 31 individuals with GPP and demonstrated effects of mutations in MPO encoding the neutrophilic enzyme myeloperoxidase (MPO). We discovered eight MPO mutations resulting in MPO -deficiency in neutrophils and monocytes. MPO mutations, primarily those resulting in complete MPO deficiency, cumulatively associated with GPP (p = 1.85E-08; OR = 6.47). The number of mutant MPO alleles significantly differed between 82 affected individuals and >4,900 control subjects (p = 1.04E-09); this effect was stronger when including IL36RN mutations (1.48E-13) and correlated with a younger age of onset (p = 0.0018). The activity of four proteases, previously implicated as activating enzymes of IL-36 precursors, correlated with MPO deficiency. Phorbol-myristate-acetate-induced formation of neutrophil extracellular traps (NETs) was reduced in affected cells (p = 0.015), and phagocytosis assays in MPO-deficient mice and human cells revealed altered neutrophil function and impaired clearance of neutrophils by monocytes (efferocytosis) allowing prolonged neutrophil persistence in inflammatory skin. MPO mutations contribute significantly to GPP's pathogenesis. We implicate MPO as an inflammatory modulator in humans that regulates protease activity and NET formation and modifies efferocytosis. Our findings indicate possible implications for the application of MPO inhibitors in cardiovascular diseases. MPO and affected pathways represent attractive targets for inducing resolution of inflammation in neutrophil-mediated skin diseases.


Assuntos
Inflamação/genética , Interleucinas/genética , Peroxidase/genética , Psoríase/genética , Dermatopatias/genética , Adulto , Animais , Citocinas/genética , Armadilhas Extracelulares/genética , Feminino , Humanos , Inflamação/patologia , Interleucina-1/genética , Interleucinas/metabolismo , Masculino , Camundongos , Mutação/genética , Neutrófilos/metabolismo , Psoríase/patologia , Doenças Raras/enzimologia , Doenças Raras/genética , Doenças Raras/patologia , Pele/enzimologia , Pele/patologia , Dermatopatias/patologia
2.
Acta Derm Venereol ; 99(4): 379-385, 2019 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-30653242

RESUMO

The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive either first oral aprepitant 80 mg/day or placebo for 4 weeks. Following a 2-week wash-out phase, the patients were crossed-over to receive the other treatment for 4 weeks. Primary efficacy criterion was the intra-individual difference between mean itch intensity (visual analogue scale) at baseline compared with the end of treatment period. Prurigo lesions, pruritus course, quality of life, patient benefits, and safety were secondary parameters. No significant differences were found between aprepitant treatment and placebo for any of the parameters investigated. Under the experimental conditions of the study, aprepitant, 80 mg daily for 4 weeks, did not have an antipruritic effect in patients with chronic prurigo. (DRKS00005594; EudraCT Number: 2013-001601-85).


Assuntos
Antipruriginosos/uso terapêutico , Aprepitanto/uso terapêutico , Antagonistas dos Receptores Histamínicos/uso terapêutico , Antagonistas dos Receptores de Neurocinina-1/uso terapêutico , Prurigo/tratamento farmacológico , Adolescente , Adulto , Idoso , Antipruriginosos/efeitos adversos , Aprepitanto/efeitos adversos , Estudos Cross-Over , Método Duplo-Cego , Resistência a Medicamentos , Feminino , Alemanha , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas dos Receptores de Neurocinina-1/efeitos adversos , Prurigo/diagnóstico , Prurigo/imunologia , Qualidade de Vida , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
3.
Acta Derm Venereol ; 99(7): 657-663, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-30834451

RESUMO

Few studies have validated standard measurement instruments for evaluation of chronic pruritus. The Chronic Pruritus Tools Questionnaire PRURITOOLS assembles a set of instruments for the assessment of pruritus, such as the visual analogue scale (horizontal 100-mm line), numerical rating scale (0-10), verbal rating scale, and information on pruritus quality and improvement during therapy. This study, with 40 subjects, analysed PRURITOOLS regarding convergent validity and test-retest reliability (60 min), followed by a feasibility questionnaire. Test-retest reliability for PRURITOOLS items was excellent (intraclass correlation coefficient 0.84-1). Strong to very strong correlations between the pruritus intensity scales indicated convergent validity. The feasibility questionnaire showed an overall acceptance of PRURITOOLS, and the majority of subjects (82.5%) considered it an appropriate questionnaire to measure pruritus. In conclusion, PRURITOOLS offers validated tools for rapid pruritus assessment in routine care or endpoints of clinical trials.


Assuntos
Prurido , Inquéritos e Questionários , Avaliação de Sintomas/métodos , Adulto , Idoso , Doença Crônica , Determinação de Ponto Final/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prurido/complicações , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Escala Visual Analógica
4.
J Am Acad Dermatol ; 79(3): 457-463.e5, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30119869

RESUMO

BACKGROUND: Chronic pruritus is a multifactorial, challenging symptom of global relevance. OBJECTIVE: The European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) investigation aimed to analyze the severity and humanistic burden of chronic pruritus in patients suffering from inflammatory dermatoses across Europe. METHODS: Prospectively collected routine data on 552 patients (with atopic dermatitis, contact dermatitis, prurigo nodularis, psoriasis vulgaris, lichen planus, or mycosis fungoides [pruritus numeric rating scale score ≥3]) from 9 European centers (in Austria, France, Germany, Italy, Poland, Russia, Spain, Switzerland, and Turkey) were analyzed by univariate and multivariate variance analyses of various itch characteristics and quality of life (as measured by the Dermatology Life Quality Index and the ItchyQoL). RESULTS: Duration, frequency, and intensity of pruritus (according to a numeric rating scale and visual analog scale) and related impairment of quality of life differed between European centers and dermatologic diagnoses (P < .05). The country in which the center was located had a greater impact on how patients evaluated pruritus intensity and quality of life than diagnosis did (P < .001). LIMITATIONS: One center per country was included. CONCLUSION: The humanistic burden of chronic pruritus in patients with inflammatory dermatoses is high. European cross-cultural factors may have a stronger influence than a specific dermatologic diagnosis on how patients rate intensity of pruritus and quality of life.


Assuntos
Efeitos Psicossociais da Doença , Prurido/etiologia , Qualidade de Vida , Índice de Gravidade de Doença , Adulto , Idoso , Doença Crônica , Estudos Transversais , Dermatite Atópica/complicações , Dermatite de Contato/complicações , Europa (Continente) , Feminino , Humanos , Líquen Plano/complicações , Masculino , Pessoa de Meia-Idade , Micose Fungoide/complicações , Prurigo/complicações , Psoríase/complicações
5.
Acta Derm Venereol ; 98(8): 722-727, 2018 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-29691587

RESUMO

Impaired sleep due to nocturnal pruritus is a common symptom in patients with chronic pruritus. However, there is no standardized, simplified instrument for assessing sleep-related problems in patients with chronic pruritus. After a literature search, we conducted 50 interviews with patients with chronic pruritus and tested 12 items most frequently used in routine sleep questionnaires. Afterwards, 2 sleep assessment questionnaires (Pittsburgh Sleep Quality Index; Regensburg Insomnia Scale) were selected for use in 88 patients with chronic pruritus with sleep impairment due to pruritus. They were completed twice; once before optimizing their individual pruritus therapy and once again after 4 weeks. During the latter survey, 21 patients reported that pruritus no longer negatively affected their sleep. These patients also achieved a significant improvement in their sleeping behaviour in the Regensburg Insomnia Scale. Therefore, the Regensburg Insomnia Scale appears to be well-suited to assessing sleep impairment in patients with chronic pruritus.


Assuntos
Prurido/complicações , Distúrbios do Início e da Manutenção do Sono/diagnóstico , Sono , Inquéritos e Questionários , Adulto , Idoso , Idoso de 80 Anos ou mais , Antipruriginosos/uso terapêutico , Doença Crônica , Feminino , Humanos , Entrevistas como Assunto , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prurido/diagnóstico , Prurido/fisiopatologia , Prurido/terapia , Reprodutibilidade dos Testes , Distúrbios do Início e da Manutenção do Sono/etiologia , Distúrbios do Início e da Manutenção do Sono/fisiopatologia , Distúrbios do Início e da Manutenção do Sono/prevenção & controle , Resultado do Tratamento
6.
Acta Derm Venereol ; 98(1): 38-43, 2018 Jan 12.
Artigo em Inglês | MEDLINE | ID: mdl-28929169

RESUMO

In order to improve diagnosis and treatment, physicians require information about the social context and quality of life of their patients. The Center for Chronic Pruritus at the University Hospital Münster achieves this goal using the electronic patient-reported outcome system "Mobile Patient Survey", which assesses pruritus and quality of life measures. The aim of this study is to evaluate the consistency and reliability of such measures. A total of 42 patients, age range 19-82 years, participated in the study and were asked to assess the measures at baseline via a paper questionnaire, and to use the "Mobile Patient Survey" at baseline and after 1 h in order to test reliability. Statistical analysis was performed using coefficient rc for metric variables and weighted kappa κw for categorical variables. The internal consistency of all measures was unaffected. It was shown that 6 out of 7 measures can be assessed without loss of reliability. It is recommended that questionnaires for electronic usage are assessed for validity and reliability.


Assuntos
Medidas de Resultados Relatados pelo Paciente , Prurido , Qualidade de Vida , Adulto , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Computadores de Mão , Coleta de Dados/métodos , Feminino , Humanos , Internet , Masculino , Pessoa de Meia-Idade , Prurido/psicologia , Reprodutibilidade dos Testes , Adulto Jovem
7.
Acta Derm Venereol ; 97(5): 601-606, 2017 May 08.
Artigo em Inglês | MEDLINE | ID: mdl-27983744

RESUMO

Performing a reliable assessment of chronic pruritus remains a challenge. Electronic diaries are often used, but many of the scales have not been validated. ItchApp© was developed for Android smartphones in order to address this lack. A total of 40 subjects with chronic pruritus completed questionnaires both on paper and with ItchApp© (verbal rating scale, numerical rating scale, dynamic pruritus score) in order to validate the software application. Strong correlations were found for test-retest reliability (intraclass correlation coefficient: 0.865-0.977) and convergent validity (Spearman's r: 0.442-0.924). A feasibility questionnaire for ItchApp© revealed a high level of user friendliness and compliance. This was confirmed in a randomized controlled trial with 68 subjects, for which the clinically important difference in the numerical rating scale values for ItchApp© was calculated (2.61 points). In summary, ItchApp© is a recently developed eDiary that can provide experts with a reliable evaluation of patients with chronic pruritus. It will be made available for future clinical trials.


Assuntos
Telefone Celular , Aplicativos Móveis , Prurido/diagnóstico , Inquéritos e Questionários , Adulto , Idoso , Antipruriginosos/uso terapêutico , Doença Crônica , Método Duplo-Cego , Feminino , Alemanha , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas dos Receptores de Neurocinina-1/uso terapêutico , Cooperação do Paciente , Satisfação do Paciente , Valor Preditivo dos Testes , Prurido/tratamento farmacológico , Prurido/fisiopatologia , Prurido/psicologia , Qualidade de Vida , Reprodutibilidade dos Testes , Projetos de Pesquisa , Índice de Gravidade de Doença , Resultado do Tratamento
12.
J Invest Dermatol ; 140(1): 203-211.e4, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31276675

RESUMO

Neurophysiological mechanisms leading to chronicity of pruritus are not yet fully understood and it is not known whether these mechanisms diverge between different underlying diseases of chronic pruritus (CP). This study aimed to detect such mechanisms in CP of various origins. A total of 120 patients with CP of inflammatory origin (atopic dermatitis), neuropathic origin (brachioradial pruritus), and chronic prurigo of nodular type, the latter as a model for chronic scratching, as well as 40 matched healthy controls participated in this study. Stimulation with cowhage induced a more intensive itch sensation compared with stimulation with other substances in all patient groups but not in healthy controls, arguing for sensitization of cutaneous mechano- and heat-sensitive C-fibers in CP. All patient groups showed a decreased intraepidermal nerve fiber density compared with controls. A decreased condition pain modulation effect was observed in all patient groups compared with controls, suggesting a reduced descending inhibitory system in CP. In sum, CP of different etiologies showed a mixed peripheral and central pattern of neuronal alterations, which might contribute to the chronicity of pruritus with no differences between pruritus entities. Our findings may contribute to the development of future treatment strategies targeting these pathomechanisms.


Assuntos
Dermatite Atópica/diagnóstico , Fibras Nervosas/patologia , Prurigo/diagnóstico , Prurido/diagnóstico , Pele/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Alérgenos/imunologia , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mucuna/imunologia , Dor , Sistema Nervoso Periférico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA